Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours

NCT05605522 is registered in ClinicalTrials.gov with 3B Pharmaceuticals GmbH as lead sponsor.

NCT NCT05605522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05605522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours
Lead sponsor
3B Pharmaceuticals GmbH
Phase
Phase 1
Overall status
Terminated
Start date
February 7, 2023
Completion date
February 20, 2025
Enrollment
19 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, ewing sarcoma, gastric cancer, neuroendocrine differentiated (ned) prostate cancer, ntsr1 expressing solid tumours, pancreatic ductal adenocarcinoma (pdac), squamous cell carcinoma of head and neck